Results

1–10 of 96 results for Anti-VEGF Agents

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Anti-VEGF Injection Prior Authorization Impacts on Retina Practices
Sabin Dang, MD
Updates from the Field
2022
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Updates from the Field
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Macular Edema as Presenting Feature of Peripheral Exudative Hemorrhagic Chorioretinopathy
Amol D Kulkarni, MD, FASRS
On Demand Cases, Courses, and Papers
2020
Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study
J. Fernando Arevalo, MD, PhD, FACS, FASRS
Annual Meeting Talks
2020
Tricks of Anti-VEGF Treatment for Retinopathy of Prematurity: How and when to Do It? When to Wait? When to Redo?
HUSEYIN YETIK, MD, PROFESSOR OF OPHTHALMOLGY
On Demand Cases, Courses, and Papers
2019
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021